Showing results (151-160 of 187) with videos related to
Sort By:
Pageof 19
Pharmaceutical Research|March 10, 2009
MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patientsKeiko Hosohata, Satohiro Masuda, Atsushi Yonezawa, et al.Clinical Lung Cancer|July 22, 2011
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusionKatsuhiro Masago, Yosuke Togashi, Masahide Fukudo, et al.Drug Metabolism and Pharmacokinetics|May 12, 2009
Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimusEriko Sato, Ikuko Yano, Masahiro Shimomura, et al.Biochemical Pharmacology|January 8, 2013
Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicityKumiko Nishihara, Satohiro Masuda, Haruka Shinke, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 9, 2008
Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injuryTakanobu Matsuzaki, Takafumi Morisaki, Wakako Sugimoto, et al.Drug Metabolism and Pharmacokinetics|August 20, 2013
Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patientsKeiko Hosohata, Miwa Uesugi, Sachiyo Hashi, et al.Pharmaceutical Research|October 26, 2005
Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritisYuji Sakurai, Hideyuki Motohashi, Ken Ogasawara, et al.Clinical Pharmacokinetics|March 28, 2013
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancerMasahide Fukudo, Yasuaki Ikemi, Yosuke Togashi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2010
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancerYosuke Togashi, Katsuhiro Masago, Masahide Fukudo, et al.Case Reports in Oncology|August 27, 2010
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene MutationKatsuhiro Masago, Yosuke Togashi, Masahide Fukudo, et al.Pageof 19